Groups of mice (males and females) of each TREM2 genotype received intracerebral injections of AD-tau at 4-months of age when Aβ plaques were abundant, followed by an evaluation of brain pathological endpoints 3 months later. The gene discussed is MAPT; the disease is Alzheimer disease.